|1.||Ittner, Lars M: 1 article (05/2014)|
|2.||Ke, Yazi D: 1 article (05/2014)|
|3.||Gladbach, Amadeus: 1 article (05/2014)|
|4.||van Eersel, Janet: 1 article (05/2014)|
|5.||Bi, Mian: 1 article (05/2014)|
|6.||Choi, Jennifer N: 1 article (01/2006)|
|7.||Omer, Charles: 1 article (01/2006)|
|8.||Gage, Earl A: 1 article (01/2006)|
|9.||Wang, Yufang: 1 article (01/2006)|
|10.||Schmidt, C Max: 1 article (01/2006)|
05/01/2014 - "Here we show that the newer MEK inhibitor PD184161 reduces cell death and altered gene expression in cultured neurons and mice undergoing excitotoxicity, and has similar protective effects in a mouse model of stroke. "
05/01/2014 - "ERK inhibition with PD184161 mitigates brain damage in a mouse model of stroke."
01/01/2006 - "PD184161 significantly suppressed tumor engraftment and initial growth (P < .0001); however, established tumors were not significantly affected. "
01/01/2006 - "Contrarily, tumor xenograft P-ERK levels following long-term (24 days) daily dosing of PD184161 were refractory to this signaling effect. "
01/01/2006 - "In vivo, tumor xenograft P-ERK levels were significantly reduced 3 to 12 hours after an oral dose of PD184161 (P < .05). "
01/01/2006 - "To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, and SKHep) and in vivo human tumor xenografts. "
|3.||Liver Neoplasms (Liver Cancer)
|1.||Heterologous Transplantation (Xenotransplantation)